Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes

Diabetes Care

Volumn 22, Issue 9, 1999, Pages 1568-1577

  Scheen, André J ^a   Lefèbvre, Pierre J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TROGLITAZONE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0345465917     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.9.1568     Document Type: Article

References (94)

1. Scheen AJ, Lefèbvre PJ: Pathophysiology of type 2 diabetes. In Handbook of Experimental Pharmacology, Oral Antidiabetics. Kuhlmann J, Puls W, Eds. Berlin, Spnnger-Verlag, 1996, p. 7-42
2. DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269, 1997
3. Mahler RJ, Adler ML: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 84: 1165-1171, 1999
4. Scheen AJ, Lefèbvre PJ: Pharmacological treatment of the obese diabetic patient. Diabet Metab 19:547-559, 1993
5. Feinglos MN, Bethel MA: Treatment of type 2 diabetes mellitus. Med Clin North Am 82:757-790, 1998
6. Scheen AJ: Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 54:355-368, 1997
7. Perfetti R, Barnett PS, Mathur R, Egan JM: Novel therapeutic strategies for the treatment of type 2 diabetes. Diabetes Metab Rev 14:207-225, 1998
8. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
9. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-665, 1998
10. Hofmann CA, Colca JR: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 15:1075-1078, 1992
11. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
12. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 26:553-573, 1997
13. Petrie J, Small M, Connell J: "Glitazones," a prospect for non-insulin-dependent diabetes. Lancet 349:70-71, 1997
14. Bethge H, Häring HU: Die Thiazolidindione: ein neues Therapieprinzip beim Typ-2-Diabetes. Drug Res 48:97-119, 1998
15. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16:179-192, 1999
16. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
17. Horikoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi K, Sasahara K: Troglitazone (CS-045): a new antidiabetic drug. Annu Rep Sankyo Res Lab 46:1-57, 1994
18. Kaneko T: Troglitazone (CS-045): a new antidiabetic agent. Horm Metab Res 29:203-213, 1997
19. Anonymous: Troglitazone for non-insulin-dependent diabetes mellitus. Med Lett Drugs Ther 39:49-51, 1997
20. Spencer CM, Markham A: Troglitazone. Drugs 54:89-101, 1997
21. Edelman S: Troglitazone: a new and unique oral anti-diabetic agent for the treatment of type II diabetes and the insulin resistance syndrome. Clin Diabetes 15:60-64, 1997
22. Levin K, Thye-Ronn P, Foot E, Beck-Nielsen H: Metabolic effects of troglitazone in NIDDM patients. Endocrinol Metab 4: 255-264, 1997
23. Chen C: Troglitazone: an antidiabetic agent. Am J Health Syst Pharm 55:905-925, 1998
24. Plosker GL, Faulds D: Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 57:409-438, 1999
25. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
26. Johnson MD, Campbell LK, Campbell RK: Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 32:337-348, 1998
27. Scheen AJ, Paquot N, Letiexhe MR, Lefèbvre PJ: Les thiazolidinediones. In Journées de Diabétologie de l'Hôtel-Dieu. Paris, Flammarion, Médecine-Sciences, 1999, p. 213-229
28. Crawford RS, Mudaliar SR, Henry RR, Chait A: Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes 48:783-790, 1999
29. Henry RR: Effects of troglitazone on insulin sensitivity. Diabet Med 13:S148-S150, 1996
30. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves P cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
31. Prigeon RL, Kahn SE, Porte D Jr: Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:819-823, 1998
32. Young MA, Lettis S, Eastmond R: Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. Br J Clin Pharmacol 45:31-35, 1998
33. Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ: Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 37:1114-1120, 1997
34. Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR: Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 37:1038-1047, 1997
35. Ott P, Ranek L, Young MA: Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol 54:567-571, 1998
36. Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14: 1083-1086, 1991
37. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-153, 1991
38. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
39. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
40. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone, a new hypoglycemic agent, in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19:151-156, 1996
41. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezène F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P, for the Troglitazone Study Group: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
42. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E: Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 62:194-202, 1997
43. Leutenegger M, Sacca L, Alderton C, Eckland D, Lettis S, on behalf of the Troglitazone Study Group: Double-masked, placebo-controlled, dose-ranging study of troglitazone 100 to 200 mg once daily in non-insulin-dependent diabetes mellitus. Curr Therap Res 58:403-416, 1997
44. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185, 1998
45. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
46. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb KW, the Troglitazone Study Group: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 83:3169-3176, 1998
47. Cominacini L, Garbin U, Pasini AF, Campagnola M, Davoli A, Foot E, Sighieri G, Sironi AM, Lo Cascio V, Ferrannini E: Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 47:130-133, 1998
48. Kumar S, Prange A, Schulze J, Lettis S, Barnett AH: Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabet Med 15:772-779, 1998
49. Kuzuya T, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T: Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 41:121-129, 1998
50. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 13:365-370, 1996
51. Corréa JCN, HilstedJ, Eckland D, Lettis S, Starkie M, Young M, for the Troglitazone Study Group: Investigation of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus. Eur J Clin Res 9:151-165, 1997
52. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, the Troglitazone Study Group, Whitcomb RW: Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 21:1462-1469, 1998
53. Buysschaert M, Bobbioni E, Starkie M, Frith L, for the Troglitazone Study Group: Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Diabet Med 16:147-153, 1999
54. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE: Effects of troglitazone and metformin on glucose and lipid metabolism. Biochem Pharmacol 54: 801-808, 1997
55. Schwartz S, Raskin P, Fonseca V. Graveline JF, for the Troglitazone and Exogenous Insulin Study Group: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998
56. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW, the Troglitazone Insulin Study Group: Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 21:1455-1461, 1998
57. Fonseca V, Graveline J, Nissel J: Long term experience with troglitazone in combination with insulin in type 2 diabetes mellitus (Abstract). Diabetes 47 (Suppl. 1):A90, 1998
58. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, the Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
59. Claudi T, Starkie M, Frith L, Kler L, Eckland DJA: Troglitazone improves cardiovascular risk profile compared with glibenclamide (Abstract). Diabet Med 14 (Suppl. 4):S30, 1997
60. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21:2135-2139, 1998
61. Cusi K, DeFronzo RA: Metformin: a review of its metabolic effects. Diabetes Rev 6: 89-131, 1998
62. Johansen K: Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 22:33-37, 1999
63. Scheen AJ: Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabet Metab 24:225-236, 1998
64. Lebovitz HE: α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 6:132-145, 1998
65. Lebovitz HE: Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Diabetes Care 22 (Suppl. 3):C41-C44, 1999
66. Nozue T, Michishita I, Minagawa F, Genda A: Troglitazone directly increases HDL cholesterol levels. Diabetes, Care 22:355-356, 1999
67. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E, Horikoshi H, Kodama T: Inhibition of oxidation of LDL density lipoprotein by troglitazone. Atherosclerosis 123:227-234, 1996
68. Tack CJ, Smits P, Demacker PN, Stalenhoef AF: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21:796-799, 1998
69. Hirano T, Yoshino G, Kazumi T: Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Intern Med 129:162-163, 1998
70. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y: Increase of lipoprotein(a) with troglitazone. Lancet 350:1748-1749, 1997
71. Ovalle F, Bell DSH: Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 22:859-860, 1999
72. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320, 1995
73. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM: Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12:181-186, 1998
74. Ishizuka T, Itaya S, Wada H, Ishizawa M, Kimura M, Kajita K, Kanoh Y, Miura A, Muto N, Yasuda K: Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 47:1494-1500, 1998
75. Minamikawa J, Yamauchi M, Inoue D, Koshiyama H: Another potential use of troglitazone in noninsulin-dependent diabetes mellitus (Letter). J Clin Endocrinol Metab 83:1041, 1998
76. Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M: Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21:1470-1474, 1998
77. Kelly IE, Han TS, Walsh K, Lean MEJ: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293, 1999
78. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917, 1998
79. Imura H: A novel antidiabetic drug, troglitazone: reason for hope and concern. N Engl J Med 338:908-909, 1998
80. Misbin RI: Troglitazone-associated hepatic failure (Letter). Ann Intern Med 130:330, 1999
81. Riddle MC: Learning to use troglitazone (Editorial). Diabetes Care 21:1389-1390, 1998
82. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, Takeuchi H: An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21:2140-2143, 1998
83. Vella A, de Groen PC, Dinneen SF: Fatal hepatotoxidty associated with troglitazone (Letter). Ann Intern Med 129:1080, 1998
84. Herrine SK, Choudhary C: Severe hepatotoxicity associated with troglitazone (Letter). Ann Intern Med 130:163-164, 1999
85. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 129:38-41, 1998
86. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36-38, 1998
87. Kuramoto K, Shimizu N, Toda G: Liver dysfunction associated with troglitazone (Noscal) (in Japanese). Rinsho Iyaka 14:461-466, 1988
88. Ault A: Troglitazone ban loses support. Lancet 353:1161, 1999
89. Scheen AJ, Paquot N, Letiexhe MR, Lefèbvre PJ: Les thiazolidinediones: quel avenir dans le traitement du diabete de type 2? Med Hyg 56:1574-1578, 1998
90. Scheen AJ, Lefèbvre PJ: Oral antidiabetic agents: a guide to selection. Drugs 55:225-236, 1998
91. Henry RR: Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 105 (Suppl. 1A):20S-265, 1998
92. Bressler R, Johnson DG: Oral antidiabetic drug use in the elderly. Drugs Aging 9:418-437, 1996
93. Petrides AS: Liver disease and diabetes mellitus. Diabetes Rev 2:2-18, 1994
94. Young MA, Eckland DJ, Eastmond R, Lettis S: Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Ann Med 30:206-212, 1998